- Conditions
- Diffuse Intrinsic Pontine Glioma, High-grade Glioma
- Interventions
- Crizotinib, Dasatinib
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 112
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, High Grade Glioma
- Interventions
- Lenalidomide, XRT, 54-59.4 Gy
- Drug · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Childhood Astrocytoma, Childhood Diffuse Intrinsic Pontine Glioma, Childhood Diffuse Midline Glioma, Childhood Glioblastoma, Childhood Malignant Glioma
- Interventions
- ATM Kinase Inhibitor AZD1390, Biospecimen Collection, Magnetic Resonance Imaging, Radiation Therapy, Survey Administration
- Drug · Procedure · Radiation + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 12 Months to 22 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Los Angeles, California • Orange, California + 17 more
- Conditions
- Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent High Grade Glioma
- Interventions
- Treatment with CD200AR-L
- Drug
- Lead sponsor
- OX2 Therapeutics
- Industry
- Eligibility
- 2 Years to 25 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Glioblastoma Multiforme, Glioma, Gliosarcoma, Malignant Brain Tumor, Ependymoma, Medulloblastoma, Diffuse Intrinsic Pontine Glioma, Primary CNS Tumor
- Interventions
- Indoximod, Temozolomide, Conformal Radiation, Cyclophosphamide, Etoposide
- Drug · Radiation
- Lead sponsor
- NewLink Genetics Corporation
- Industry
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Orlando, Florida • Atlanta, Georgia + 2 more
- Conditions
- Diffuse Intrinsic Pontine Glioma, Recurrent Anaplastic Astrocytoma, Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent Medulloblastoma
- Interventions
- Fimepinostat, Therapeutic Conventional Surgery
- Drug · Procedure
- Lead sponsor
- Sabine Mueller, MD, PhD
- Other
- Eligibility
- 3 Years to 39 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 18
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 15 more
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Glioblastoma, Gliosarcoma
- Interventions
- Adavosertib, Laboratory Biomarker Analysis, Pharmacological Study, Radiation Therapy
- Drug · Other · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 37 Months to 21 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Los Angeles, California • Orange, California + 19 more
- Conditions
- Brain Cancer, Brain Stem Tumors, Pontine Tumors
- Interventions
- Rindopepimut
- Biological
- Lead sponsor
- Paul Graham Fisher
- Other
- Eligibility
- 3 Years to 18 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Diffuse Intrinsic Pontine Glioma, Gliosarcoma
- Interventions
- 3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Vorinostat
- Radiation · Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 37 Months to 21 Years
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2021
- U.S. locations
- 174
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 129 more
- Conditions
- Diffuse Intrinsic Pontine Glioma
- Interventions
- Tumor Lysate Vaccine, Imiquimod, Radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 3 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Glioma, Glioma of Brain, Cancer, Pediatric Cancer, Pediatric Brain Tumor, Astrocytoma, Glioblastoma, Hemispheric
- Interventions
- Specialized tumor board recommendation
- Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 12
- States / cities
- San Diego, California • San Francisco, California • Washington D.C., District of Columbia + 9 more
- Conditions
- Central Nervous System Tumor, Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, Ependymoma, Medulloblastoma, Childhood, Germ Cell Tumor, Atypical Teratoid/Rhabdoid Tumor, Primitive Neuroectodermal Tumor, Choroid Plexus Carcinoma, Pineoblastoma, Childhood, Glioma
- Interventions
- SCRI-CARB7H3(s); B7H3-specific chimeric antigen receptor (CAR) T cel
- Biological
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 1 Year to 26 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2042
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- High Grade Glioma, Diffuse Intrinsic Pontine Glioma
- Interventions
- Larotrectinib, Larotrectinib surgical
- Drug · Procedure
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2036
- U.S. locations
- 10
- States / cities
- Aurora, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
- Conditions
- Refractory Cancer, Refractory Neoplasm, Cancer Pediatric, Refractory Tumor, Pediatric Cancer, Pediatric Brain Tumor, Neuroblastoma, Neuroblastoma Recurrent, Pediatric Lymphoma, Pediatric Meningioma, Diffuse Intrinsic Pontine Glioma
- Interventions
- 9-ING-41, Irinotecan, Temozolomide, Cyclophosphamide, Topotecan
- Drug
- Lead sponsor
- Actuate Therapeutics Inc.
- Industry
- Eligibility
- Up to 22 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 9
- States / cities
- San Francisco, California • Aurora, Colorado • Chicago, Illinois + 6 more
- Conditions
- Anaplastic Astrocytoma, Anaplastic Ependymoma, Astrocytoma, Grade II, Ependymoma, Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma, Oligodendroglioma, Brainstem Tumors
- Interventions
- imetelstat sodium
- Drug
- Lead sponsor
- Pediatric Brain Tumor Consortium
- Network
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 8 more
- Conditions
- Diffuse Intrinsic Pontine Glioma, Glioma, Malignant
- Interventions
- Dordaviprone (ONC201)
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 8
- States / cities
- San Francisco, California • Miami, Florida • Atlanta, Georgia + 5 more
- Conditions
- Glioblastoma, Medulloblastoma, Ependymoma, Diffuse Intrinsic Pontine Glioma
- Interventions
- Indoximod, Partial Radiation, Full-dose Radiation, Temozolomide, Cyclophosphamide, Etoposide, Lomustine
- Drug · Radiation
- Lead sponsor
- Theodore S. Johnson
- Other
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 5
- States / cities
- Augusta, Georgia • Druid Hills, Georgia • Boston, Massachusetts + 2 more
- Conditions
- Diffuse Intrinsic Pontine Glioma, Diffuse Pontine and Thalamic Gliomas, Diffuse Midline Glioma, H3 K27M-Mutant
- Interventions
- Panobinostat 15 MG, Focused Ultrasound with neuro-navigator-controlled sonication
- Drug · Device
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 4 Years to 21 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Glioma, Diffuse Intrinsic Pontine Glioma
- Interventions
- Panobinostat, Everolimus
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 2 Years to 30 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Diffuse Intrinsic Pontine Glioma, DIPG, Brain Tumor, CNS Tumor, Central Nervous System Tumor, Pediatric Cancer, Adult Cancer Patients, CNS Tumor, Childhood, CNS Tumor, Adult, Brainstem Glioma, Diffuse Midline Glioma, DMG
- Interventions
- BCB-276
- Biological
- Lead sponsor
- BrainChild Bio, Inc
- Industry
- Eligibility
- 1 Year to 26 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 3 more
- Conditions
- Relapsed Solid Tumor, Refractory Solid Tumor
- Interventions
- Abemaciclib, Irinotecan, Temozolomide, Dinutuximab, GM-CSF
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- Up to 21 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Los Angeles, California • Oakland, California + 9 more
- Conditions
- Medulloblastoma, Glioblastoma Multiforme, Anaplastic Astrocytoma, High-grade Astrocytoma NOS, Anaplastic Oligodendroglioma, Anaplastic Ependymoma, Ependymoma, Diffuse Intrinsic Pontine Glioma
- Interventions
- SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years, SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years, SurVaxM for patients with non-relapsed DIPG post radiation-therapy ages ≥1 and ≤21 years
- Biological
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Palo Alto, California • Aurora, Colorado + 10 more
- Conditions
- High-grade Glioma, Medulloblastoma, Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
- Interventions
- Atovaquone, Radiation Therapy
- Drug · Radiation
- Lead sponsor
- Emory University
- Other
- Eligibility
- 2 Years to 25 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Neuroblastoma, Diffuse Intrinsic Pontine Glioma
- Interventions
- Tumor-specific ex vivo expanded autologous lymphocyte transfer (TTRNA-xALT)
- Biological
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2032
- U.S. locations
- 3
- States / cities
- Gainesville, Florida • Charlotte, North Carolina • Hershey, Pennsylvania